comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 15:38:59 - browse：5

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Sen. Paul opposes bill to ban Chinese biotechs

WSS

Poor hospice wound care hurts patients and families

Air quality improving but still lags in Black, Hispanic communities

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Ransomware attacks on hospitals: Study outlines patient impact

CRISPR pioneers react to Casgevy, first gene

Astellas still sees hope in its gene therapy after four deaths

focus

comprehensive

Wikipedia

Heart attack and stroke risk calculators need revising

A daunting task: navigating dual Medicare, Medicaid eligibility

How to save PrEP access — and even expand it

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

NEJM study link tiny plastics in blood vessels to heart problems

As demand for Covid shots wanes, Moderna seeks its next success

First medicine developed to treat MASH expected to be approved soon

Cancer drug shortages should be causing more outrage

Novo Nordisk obesity pill bests Wegovy in early trial

knowledge

CRISPR pioneers react to Casgevy, first gene

Air quality improving but still lags in Black, Hispanic communities

Sen. Paul opposes bill to ban Chinese biotechs

Poor hospice wound care hurts patients and families

Childhood cancer progress stalls for Black, Hispanic kids: Report

Weight loss drug costs may need more research, senator suggests

hotspot

hotspot

explore

focus